Cisapride (R 51619): Dual 5-HT4 Agonist and hERG Inhibitor for Cardiac Electrophysiology Research

Executive Summary: Cisapride (R 51619) is a nonselective 5-HT4 receptor agonist and potent inhibitor of the hERG potassium channel, widely used in cardiac electrophysiology and gastrointestinal motility research (APExBIO). Its high solubility in DMSO (≥23.3 mg/mL) and ethanol (≥3.47 mg/mL), combined with water insolubility, mandates precise handling protocols (APExBIO). Cisapride demonstrates high purity (99.70%) and consistent performance in iPSC-derived cardiomyocyte assays for predictive cardiotoxicity (Grafton et al., 2021). Cardiotoxicity linked to hERG inhibition is a primary reason for late-stage drug attrition, underscoring the compound’s value in de-risking drug discovery (Grafton et al., 2021). APExBIO supplies Cisapride (R 51619) with full quality control documentation, facilitating reproducibility in preclinical workflows.

Biological Rationale

Cisapride (R 51619) is designed to interrogate two critical signaling axes: serotonergic (5-HT4) and cardiac potassium (hERG) channels. The 5-HT4 receptor is a G protein-coupled receptor involved in gastrointestinal motility and cardiac function (Cisapride: Advancing Cardiac Electrophysiology). hERG (human ether-à-go-go-related gene) encodes the KCNH2 potassium channel, essential for cardiac repolarization. Inhibition of hERG channels can prolong the QT interval and increase arrhythmia risk. Predicting and mitigating hERG-mediated cardiotoxicity is a regulatory requirement in modern drug development (Grafton et al., 2021). Cisapride’s dual activity enables simultaneous assessment of serotonergic and electrophysiological pathways in both health and disease models.

Mechanism of Action of Cisapride (R 51619)

Cisapride acts as a nonselective agonist at the 5-HT4 receptor, stimulating adenylate cyclase via Gs protein coupling. This leads to increased intracellular cAMP and enhanced GI smooth muscle contraction (Cisapride: Mechanistic Insights and Strategic Research). Concurrently, Cisapride is a high-affinity inhibitor of the hERG potassium channel (KCNH2), leading to delayed rectifier potassium current (I_Kr) blockade. This action prolongs the cardiac action potential and the QT interval, providing a model for drug-induced arrhythmogenesis. Its inhibitory concentration (IC₅₀) for hERG channel blockade is in the low micromolar range, depending on assay conditions (APExBIO).

Evidence & Benchmarks

• Cisapride induces dose-dependent blockade of the hERG potassium channel in human cell assays, with measurable effects at sub-micromolar concentrations (Grafton et al., 2021).
• In high-content phenotypic screens using iPSC-derived cardiomyocytes, Cisapride reliably elicits a cardiotoxic phenotype, serving as a positive control compound (Grafton et al., 2021).
• Prolongation of the QT interval and action potential duration by Cisapride is reproducible across in vitro and preclinical models (see Figure 4, Grafton et al., 2021).
• APExBIO’s Cisapride (R 51619) B1198 product is supplied at ≥99.70% purity, with HPLC, NMR, and MSDS documentation supporting batch-to-batch consistency (APExBIO).
• Unlike immortalized lines, iPSC-derived cardiomyocytes exposed to Cisapride reproduce human-like cardiotoxic responses, enabling translational relevance in screening (Grafton et al., 2021).

This article extends the mechanistic detail provided in "Cisapride: Precision Tools for Cardiac Electrophysiology" by adding updated benchmarks from recent high-content screening studies and best practices for integration with iPSC-CM assays.

Applications, Limits & Misconceptions

Cisapride (R 51619) is widely used for:

• Cardiac electrophysiology research—especially QT prolongation and arrhythmia modeling.
• Predictive cardiotoxicity screening in iPSC-derived cardiomyocytes (Grafton et al., 2021).
• Elucidation of 5-HT4 receptor-mediated signaling in GI and cardiac tissues (Cisapride: Mechanistic Insights).
• Benchmarking new pharmacological agents for hERG channel interaction risk.

Common Pitfalls or Misconceptions

• Cisapride is not selective for the 5-HT4 receptor; it may interact with other serotonergic and cardiac targets.
• Water insolubility can cause precipitation in aqueous buffers; always use DMSO or ethanol as solvents at validated concentrations (APExBIO).
• Long-term storage of Cisapride solutions (even at -20°C) is discouraged due to degradation; prepare fresh aliquots before use.
• Not intended for clinical or veterinary use; strictly for research applications.
• Cardiotoxicity findings in iPSC-derived models may not fully capture complex in vivo pharmacodynamics.

This article clarifies misconceptions discussed in "Cisapride: Next-Generation Insights for Cardiac Research" by providing explicit boundaries on selectivity, solubility, and translational limits.

Workflow Integration & Parameters

Cisapride (R 51619) is provided by APExBIO as a solid compound with a molecular weight of 465.95 g/mol. For experimental use, dissolve at ≥23.3 mg/mL in DMSO or ≥3.47 mg/mL in ethanol, and store aliquots at -20°C. Avoid repeated freeze-thaw cycles and do not store diluted solutions long term (APExBIO).

In predictive cardiotoxicity assays, typical working concentrations range from 0.01 to 30 μM. Use iPSC-derived cardiomyocyte models for highest translational relevance. High-content imaging and deep learning platforms can rapidly quantify phenotypic changes, as validated in recent screens (Grafton et al., 2021).

For further protocol details, refer to the product page for Cisapride (R 51619) B1198. This article updates the strategic recommendations outlined in "Cisapride: Mechanistic Insights for Cardiac Electrophysiology" by emphasizing best practices for compound handling, iPSC-CM assay design, and data interpretation.

Conclusion & Outlook

Cisapride (R 51619) remains a benchmark tool for dissecting 5-HT4 receptor signaling and hERG channel inhibition in preclinical research. Its validated performance in iPSC-derived cardiomyocyte assays supports early de-risking of drug candidates with potential cardiotoxicity. Stringent handling and storage protocols are essential to maintain compound integrity and reproducibility. As deep learning and high-content screening technologies advance, the role of Cisapride in translational safety pharmacology will continue to expand (Grafton et al., 2021).